ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- have ovarian cancer of clear cell, endometrioid or carcinosarcoma type and
- are aged over 18
- have a tissue sample available from your original diagnosis or are willing to have a biopsy to obtain another one
- have cancer that has come back after previous treatment with a platinum based chemotherapy (Carboplatin or Cisplatin)
- have an area of cancer seen on scan that can be measured
- are in good general health
- are able to swallow tablets or capsules
- have not previously had treatment with either an ATr inhibitor or PARP inhibitor
Those with other types of gynaecological cancers can also take part in the trial.
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
Recruitment to this trial is currently paused.
The researchers in this trial are looking to find how out how well the drug ceralasertib (on its own) and the combination of the drugs ceralasertib and olaparib work in rarer types of gynaecological cancers.
The drugs used in this clinical trial are:
- Ceralasertib is a drug called an ATR inhibitor. It is a type of targeted therapy. ATR proteins help repair DNA damage in healthy cells. In the laboratory we know that ATR inhibitors can kill cancer cells that have a change in the ARID1A gene
- Olaparib is a drug called a PARP inhibitor. It is also a type of targeted therapy. The PARP inhibitors are already used in clinical practice to treat certain types of ovarian cancer
If you participate in this trial you will have either:
- Ceralasertib on its own
- Ceralasertib with Olaparib
Whether you will have Ceralasertib on its own or with Olaparib depends on 3 major factors:
- whether or not your tumour has the abnormal ARIDA1 protein. The researchers will find this out by examining a tumour sample either from your diagnosis or obtained as part of the trial.
- the subtype of your ovarian cancer
- how well those people already on the trial are responding to the Cerlasertib on its own.
In addition to taking the study drug(s) you will also need to be willing to have:
- additional tests, these may include blood tests, ECGs, CT scans, urine tests and a biopsy (if there isn't a previous one available)
- additional visits to see a doctor
